2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1363

Serum Adipokines in Juvenile Dermatomyositis Are Associated with Disease Activities and Cardiac Function
Abstract Number: 564

Serum Adiponectin and Body Composition in a Group of Patients with Rheumatoid Arthritis: Relationship Between Disease Parameters
Abstract Number: 2856

Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms
Abstract Number: 1677

Serum Complement C3 Component As a Potential Disease Activity Marker in Psoriatic Arthritis
Abstract Number: 2328

Serum Ferritin Levels, Distribution of Ground Glass Opacities and New Development of Lung Infiltration during Therapy Predict Prognosis of Interstitial Lung Disease in Anti-MDA5 Ab Positive Dermatomyositis
Abstract Number: 2907

Serum KL-6 Levels in Interstitial Lung Diseases (ILDs) Associated to Connective Tissue Diseases (CTDs)
Abstract Number: 2892

Serum Level of KL-6, a Biomarker of Interstitial Lung Disease (ILD), Is Higher in Diffuse SSc Than in Limited SSc and RA Even When the Activity of ILD Is Low
Abstract Number: 1529

Serum Levels of P-Glycoprotein Are Associated with Disease Activity in Rheumatoid Arthritis
Abstract Number: 2347

Serum Levels of Resistin Are Associated with Synovial Inflammation and Knee Structural Changes in Patients with Symptomatic Knee Osteoarthritis
Abstract Number: 3250

Serum MCP-1 Levels Predict Long-Term Progression of Interstitial Lung Disease in Systemic Sclerosis
Abstract Number: 2585

Serum MMP-3 and OPG As Predictors of Response to Traditional Dmards in a Treatment NaïVe Early Rheumatoid Arthritis Cohort
Abstract Number: 1544

Serum Omentin-1 Levels and Metabolic Syndrome in Women with Rheumatoid Arthritis
Abstract Number: 364

Serum Sclerostin Levels in Rheumatoid Arthritis (RA) and Its Correlation with Disease Activity and Bone Mineral Density
Abstract Number: 2287

Serum Urate and Its Association with Endothelial Dysfunction in Young Adults
Abstract Number: 2297

Serum Urate and Its Association with Race in Young Adults: Baseline Analysis from a Randomized Clinical Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].